Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals has released the investor presentation that Managing Director and Group CEO Dr. Christian Behrenbruch will deliver at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with the session to be webcast live and available on demand via the company’s investor relations site. Alongside the conference materials, Telix has also published a comprehensive overview of its therapeutic pipeline assets and confirmed it will report fourth-quarter 2025 financial results on 20 January 2026, signalling an active period of investor engagement and increased transparency around its development programs and financial performance.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$25.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a Melbourne-headquartered biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical technologies. With operations spanning the United States, United Kingdom, Brazil, Canada, Europe and Japan, the ASX- and Nasdaq-listed company focuses on addressing significant unmet medical needs in oncology and rare diseases through a portfolio of clinical and commercial-stage products.
YTD Price Performance: 0.36%
Average Trading Volume: 1,775,869
Technical Sentiment Signal: Sell
Current Market Cap: A$3.81B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.